| Code | CSB-RA024405MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to VHB937, designed for research targeting Triggering Receptor Expressed on Myeloid cells 2 (TREM2). TREM2 is an immunomodulatory receptor predominantly expressed on microglia in the central nervous system and on myeloid cells in peripheral tissues. This receptor plays crucial roles in phagocytosis, inflammatory response regulation, and lipid sensing. TREM2 has emerged as a significant player in neurodegeneration, particularly in Alzheimer's disease, where loss-of-function mutations are associated with increased disease risk and altered microglial function. Additionally, TREM2 is implicated in other neurodegenerative conditions, including frontotemporal dementia and Nasu-Hakola disease, as well as in cancer immunity and metabolic disorders.
VHB937 serves as the reference antibody for this biosimilar product and has been utilized in neuroscience and immunology research to investigate TREM2-mediated signaling pathways and microglial responses. This antibody provides researchers with a reliable tool for exploring TREM2's role in neuroinflammation, immune cell activation, and disease pathogenesis across various experimental models.
There are currently no reviews for this product.